Oculis Holding AG

Stage 4 · Declining · week 6

As of Oct 22, 2026, Oculis Holding is in Stage 4, the downtrend phase, now in week 6 (since Sep 17, 2026). It closed at $8.09, 75.2% below its 52-week high and below its 200-day average, which is falling.

$8.09

+2.80% today

$498M · Small cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is OCS early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S2 27w

S2 24w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S2 6w → S3 6w → S4 8w → S1 6w → S2 8w → S3 6w → S2 7w → S3 8w → S1 3w → S2 27w → S3 10w → S2 7w → S3 2w → S4 7w → S1 4w → S2 24w → S3 3w → S2 2w → S3 3w → S4 10w → S1 1w → S4 5w current

Total tracked: 164 weeks across 22 stage runs.

OCS among Biotechnology404th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…404	OCSOculis Holding AG	Stage 4 · wk 6	18	−19.0%

vs 52W High

-75.2%

$7.17 lo$32.65 hi

75.2% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 6

1w13w26w

Week 6, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-58.0%

200 DMA: $19.26 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

1.73x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-19.0%

-27.3%

-69.8%

YTD

-59.5%

-62.9%

Scan Membership

Breakout Watch

Latest: 2025-06-16

6 appearances in last 60 days. First seen: 2022-03-21.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 6 · Vol 1.73x

2026-10-21S4

Wk 5 · Vol 1.18x

2026-10-20S4

Wk 5 · Vol 1.31x

2026-10-19S4

Wk 5 · Vol 1.17x

2026-10-16S4

Wk 5 · Vol 1.20x

2026-10-15S4

Wk 5 · Vol 2.28x

2026-10-14S4

Wk 4 · Vol 2.12x

2026-10-13S4

Wk 4 · Vol 1.33x

2026-10-12S4

Wk 4 · Vol 1.18x

2026-10-09S4

Wk 4 · Vol 0.66x

2026-10-08S4

Wk 4 · Vol 1.88x

2026-10-07S4

Wk 3 · Vol 0.71x

Moving averages & range

50 DMA

$10.36

200 DMA

$19.26

52W High

$32.65

52W Low

$7.17

5D Low

$7.29

Resistance levels (recent highs)

20d High

$9.34

60d High

$13.57

120d High

$32.65

250d High

$32.65

Next resistance

+15.5%

to 20d High

ROE

-43.7%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 1.9

Oculis Holding: quick answers

What stage is Oculis Holding in?

As of Oct 22, 2026, Oculis Holding (OCS) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 17, 2026 and is in week 6. What the four stages mean

Is Oculis Holding in an uptrend?

No. Oculis Holding is in a Stage 4 downtrend. It trades 58.0% below its 200-day average, which is falling.

How far is Oculis Holding from its 52-week high?

Oculis Holding closed at $8.09 on Oct 22, 2026, 75.2% below its 52-week high of $32.65. Its 52-week low is $7.17.

How has Oculis Holding performed over the past year?

As of Oct 22, 2026, Oculis Holding is down 62.9% over the past year and down 59.5% so far in 2026.

Which sector and industry is Oculis Holding in?

Oculis Holding is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.